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Chiral  amino  alcohols  are  structural  motifs  present  in sphingolipids,  antibiotics,  and  antiviral  glycosi-
dase  inhibitors.  Their  chemical  synthesis  presents  several  challenges  in  establishing  at  least  two  chiral
centres.  Here  a de  novo  metabolic  pathway  using  a transketolase  enzyme  coupled  with  a  transaminase
enzyme  has  been  assembled.  To  synthesise  this  motif  one  of the  strategies  to  obtain  high  conversions
from  the  transaminase/transketolase  cascade  is the  use of hydroxypyruvate  (HPA)  as  a two-carbon  donor
for the  transketolase  reaction;  although  commercially  available  it is  relatively  expensive  limiting  appli-
cation  of  the pathway  on  an  industrial  scale.  Alternately,  HPA  can  be  synthesised  but this  introduces  a
further  synthetic  step.  In this  study  two  different  biocatalytic  strategies  were  developed  for  the  synthesis
of  (2S,3R)-2-amino-1,3,4-butanetriol  (ABT)  without  adding  HPA  into  the  reaction.  Firstly,  a sequential
cascade  of  three  enzymatic  steps  (two transaminases  and  one  transketolase)  for the  synthesis  of  ABT
from  serine,  pyruvate  and  glycolaldehyde  as substrates.  Secondly,  a two-step  recycling  cascade  where
serine  is used  as  donor  to aminate  erythrulose  (catalysed  by  a transketolase)  for  the simultaneous  syn-
thesis  of  ABT  and  HPA.  In  order to test  the novel  pathways,  three  new  transaminases  are  described,  two
-transaminases  able  to  accept  a broad  range  of amine  acceptors  with  serine  as amine  donor;  and  an  -
transaminase,  which  showed  high  afﬁnity  towards  serine  (KM: 18 mM)  using  pyruvate  as  amine  acceptor.
After  implementation  of  the  above  enzymes  in the  biocatalytic  pathways  proposed  in  this  paper,  the  two-
step  recycling  pathway  was  found  to  be the  most  promising  for its integration  with  E. coli  metabolism.
It  was  more  efﬁcient  (10-fold  higher  conversion),  more  sustainable  and  cost-effective  (use  of  low  cost
natural  substrates  and only  two enzymes),  and  the reaction  could  be performed  in  a  one-pot  system.
© 2015  The  Authors.  Published  by  Elsevier  Inc. This  is  an open  access  article  under  the  CC  BY  license. Introduction
Chiral amino alcohols are key functionalities in several sphin-
olipids, antibiotics such as chloramphenicol and thiamphenicol,
nd antiviral glycosidase inhibitors such as the deoxynojirimycin
amily among others [1]. These compounds can be synthesized
y either chemical or biocatalytic methods. Among the various
hemical methods available, diastereoisometric crystallisation [2]
nd asymmetric hydrogenation [3] have been established. How-
ver, the low maximum yield (up to 50%) and the pre-activation
f the substrate as well as the high price of the transition metal
∗ Corresponding author.
E-mail addresses: maria.torres.09@ucl.ac.uk (M.F. Villegas-Torres),
.c.hailes@ucl.ac.uk (H. Hailes), j.ward@ucl.ac.uk (J. Ward).
ttp://dx.doi.org/10.1016/j.enzmictec.2015.07.003
141-0229/© 2015 The Authors. Published by Elsevier Inc. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
and recycling/disposal, respectively, are their main disadvantages
[2]. Biocatalysis on the other hand allows the development of sus-
tainable manufacturing processes and the production of highly
enantiopure compounds in high yields due to the enzymes chemo-
, regio-, and enantioselectivity [4]. Monoamine oxidases, lyases,
transaminases [2] and the recently described imine reductases
[5,6] and norcoclaurine synthase [7] have been implemented in
the synthesis of chiral amino alcohols. Among them, transaminases
are industrially desirable as they have broad substrate speciﬁcity
and high levels of regio- and stereoselectivity, in spite of their
unfavourable equilibrium and substrate and/or product inhibi-
tion [8–10]. They have been successfully used at an industrial
scale replacing chemical synthesis, e.g., in sitagliptin manufacture.
Sitagliptin is an antidiabetic compound, which has been chemically
synthesised by rhodium-catalysed asymmetric enamine hydro-
genation at 250 psi. Following various rounds of substrate walking
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pig. 1. Reaction scheme for the synthesis of ABT by a three-step sequential cascade. A
onor,  producing alanine and HPA. Then, a transketolase enzyme (TK) uses HPA and
CV2025) catalyses the amination of the formed ERY with MBA, synthesizing ABT a
nd directed evolution, an -transaminase was engineered and
uccessfully employed in the synthesis of sitagliptin at higher
ields and productivity, and lower waste compared to the chemical
ethod [11]. Another example is for the synthesis of valinol, a 1,2
mino alcohol previously synthesised by valine reduction employ-
ng agents like LiAlH4. Recently a sustainable biocatalytic process
as described using several -transaminases leading to optically
ure enantiomers and 99% yield when the R-conﬁguration was  pro-
uced and 94% conversion when the S-isomer was synthesised [12].
In addition to single step biotransformations, transaminases
ave been coupled to additional enzymatic steps broadening the
cope of the chemicals produced from inexpensive substrates.
or instance, the synthesis of l-norephedrine was  performed
y coupling an R-selective pyruvate decarboxylase from Saccha-
omyces cerevisiae [13] or an acetohydroxyacid synthase I from
scherichia coli [14] with an -transaminase. In the ﬁrst step
enzaldehyde and pyruvate were used as substrates for the pro-
uction of l-phenylacetylcarbinol, which was then aminated by
he transaminase synthesising l-norephedrine. The latter step used
lanine as amine donor releasing pyruvate as co-product, which
as further employed as a substrate for the ﬁrst reaction gener-
ting a recycling mechanism able to shift the equilibrium of the
ascade [13,14].
In our group we have been studying de novo pathways cou-
ling a transketolase enzyme with a transaminase enzyme. In an
arly study, a one-pot in vivo approach was performed for the pro-
uction of 2-amino-1,3,4-butanetriol (ABT), using glycolaldehyde
GA) and -hydroxypyruvate (HPA) as substrates for the transke-
olase step, followed by transamination of the erythrulose product
ith S-()-methylbenzylamine (MBA) as amine donor, employing
 transaminase from Pseudomonas putida.  In spite of the successful
ynthesis of the amino alcohol using E. coli as whole cell biocatalyst,
he resulting yield (∼21% mol/mol) was low due to a long reaction
ime for the transaminase step, possibly because of its low afﬁnity
owards the substrates, or side reactions consuming erythrulose
15]. Following the description of the CV2025 transaminase from
hromobacterium violaceum [16], this enzyme was implemented
n the above transketolase/transaminase pathway, and with the
eplacement of MBA  with isopropylamine (IPA) as amine donor,
 4-fold increase in the percentage of conversion (from 21% to 87%)
or the synthesis of ABT was achieved [17].
In both studies, the reaction was performed in resting cells with-
ut any host optimisation, requiring the supply of all substrates
nvolved, namely MBA  or IPA, GA and HPA. Both MBA  and IPA are
on-natural compounds; HPA is available within the cell in the
hosphorylated form; and GA is found in the biosynthetic path-ransaminase (DGEO 0713) catalyses the amination of pyruvate with serine as amine
 substrates for the synthesis of ERY with release of CO2. Finally, an -transaminase
tophenone.
way of folic acid (in pentose and glucuronate interconversions) and
vitamin B6, glyoxylate and dicarboxylate metabolism [18]. There-
fore, to perform de novo pathway integration, both amine donor
and keto donor for the transaminase and transketolase reactions
would have to be provided by either an additional enzymatic step
or an alternative donor than the ones previously employed.
In this work, we  have in vitro studied different strategies to
supply non-phosphorylated HPA to the previously described enzy-
matic pathway, as well as the possibilities of using alternative
amine donors for the transaminase step. The ﬁrst system (Fig. 1)
involved the addition of a serine transaminase that can produce
HPA by the amination of pyruvate using serine as amine donor
followed by the previously described cascade [15,17], generating
a three step pathway. The second reaction system (Fig. 2) corre-
sponds to a two-step recycling system of the co-product. Thus by
aminating erythrulose with serine, ABT and HPA could be synthe-
sised simultaneously, the latter can be further consumed during the
transketolase reaction recycling this substrate (HPA) in a two-step
pathway. The conversion of HPA by transketolase and the release
of CO2 in the reaction should effectively drive the enzyme pathway
to the formation of ABT.
To achieve the synthesis of ABT as a case study using the
proposed alternative pathways, three new transaminases were
identiﬁed and characterised in terms of their kinetic parameters
and amine acceptor proﬁle. The best candidates were tested in vitro
as possible biocatalysts of the novel cascades described in this work.
2. Materials and methods
2.1. Strains and plasmids
Strains and plasmids used in this study are described in Table 1.
2.2. pQR plasmids construction
Each of the transaminase genes, described in Table 1, was
ampliﬁed by PCR implementing the primers illustrated in Table 2.
PCR products were incorporated into pCR4-TOPO (Life Technolo-
gies, USA) according to the manufacturer recommendations. Before
transferring the gene to pET29a+ (Novagen, USA) expression vector,
each sequence was conﬁrmed by gene sequencing performed by the
Wolfson Institute at UCL. pQR plasmids were ﬁnally constructed by
ligating the plasmid pET29a+, previously restricted with NdeI and
XhoI (New England BioLabs, UK), with the corresponding fragment
obtained from the restriction of pCR4-TOPO::PCR with the same
restriction enzymes.
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Fig. 2. Reaction scheme for the synthesis of ABT by a recycling de novo pathway. A novel -transaminase (RSPH17019 3177) catalyses the amination of erythrulose using
serine  as amine donor, synthesising ABT and HPA. Then, HPA is employed as substrate with GA for the synthesis of erythrulose catalysed by transketolase (TK). The side
reaction catalysed by RSPH17029 3177 where GA is aminated to synthesise ethanolamine and HPA is highlighted in red, and the recycling reaction is highlighted in blue.
Table 1
Strains and plasmids used in this study.
Strains/plasmidsa Locus tag (enzyme) Gene source and GenBank number Transaminase type
E. coli BL21-Gold (DE3)b
E. coli Rossetta-2 (DE3)c
pQR801 CV2025 Chromobacterium violaceum DSM30191 AAQ59697.1 MBA:pyruvate transaminase
pQR958 PP 3718 Pseudomonas putida DSM6125 AAN69315.1 Acetylornithine aminotransferase
pQR977 DGEO 0713 Deinococcus geothermalis DSM11300 ABF45015.1
pQR980 DGEO 1416 Deinococcus geothermalis DSM11300 ABF45711.1 Acetylornithine aminotransferase
pQR1005 KPN 00255 Klebsiella pneumoniad ABR75708.1 4-aminobutyrate aminotransferase
pQR1008 KPN 00955 Klebsiella pneumoniad ABR76391.1 Aspartate aminotransferase
pQR1010 KPN 01493 Klebsiella pneumoniad ABR76925.1 Succinylornithine transaminase
pQR1011 KPN 03745 Klebsiella pneumoniad ABR79132.1 Acetylornithine aminotransferase
pQR1018 PPUTGB1 2189 Pseudomonas putida DSM6125 ABY98090.1 Acetylornithine aminotransferase
pQR1019 RSPH17025 2835 Rhodobacter sphaeroides ATCC17025 ABP71721.1
pQR1020 PPUT 2046 Pseudomonas putida DSM6899 ABQ78186.1 Acetylornithine aminotransferase
pQR1021 RSPH17029 3177 Rhodobacter sphaeroides ATCC17025 ABN78277.1
a Construction of the pQR expression plasmids is described in Section 2.
b Agilent Technologies, USA55.
c Novagen, USA
d J. Ward collection. Equivalent strain to Klebsiella pneumonia DSM 30,104.
Table 2
Primers used for the transaminase cloning.
Plasmid Forward primer Reverse primer
pQR801 5-CATATGCAGAAGCAACGTACGACCAGCC-3 5-CTCGAG CTAAGCCAGCCCGCGCGCCTTCAG-3
pQR958 5-CATATGGCCACCCCAAGCAAAGCATTCG-3 5-CTCGAGGCCTTGGTACAGGCCAAGCGCCGT-3
pQR977 5-CAT ATGAGTGAGCGCCCACTGCC-3 5-CTCGAGAGCCTCGCACCCAGCCATTTCCCG-3
pQR980 5-CATATGACGGGCACGAAGACCAA-3 5-CTCGAGCGTCTGCTTGTCTTCCCGCAGCTC-3
pQR1005 5-CATATGAACAGCAATAAAGCAAT-3 5-CTCGAG CTGTTTCGCCTCGCTAAAGC-3
pQR1008 5-CATATGTTTGAGAACATTACCG-3 5-CTCGAGTACGGCGACGATGGCTTCGCACAG-3
pQR1010 5-CATATGTCAGGCAGTATGACTCG-3 5-CTCGAG GGTTAAGCGGGCAACGGCGCGATC-3
pQR1011 5-CATATGGCAACTGAACAACCGGC-3 5-CTCGAGGTTAATCACCTTTGCCACCGCCTG-3
pQR1018 5-CATATGGCCACCCCAAGCAAAGC-3 5-CTCGAGGCCCTGGTACAGGCCAAGCGCAGT-3
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ppQR1019 5-CATATGGCGCTGAATGACGCGGC-3 
pQR1020 5-CATATGGCCACCCCAAGCACAGC-3 
pQR1021 5-CATATGACGCGGAATGACGCGAC-3 
.3. Growth media, culture conditions and enzyme puriﬁcation
Glycerol stocks of all cultures were stored at −80 ◦C in 2xYT
roth (16 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl) containing
0% glycerol. Overnight cultures were prepared in 2xYT broth sup-
lemented with appropriate antibiotics. Cells were subcultured
sing 1% v/v inoculum in 2 l shake ﬂasks containing 500 ml of
he same supplemented broth at 37 ◦C and 250 rpm. Transami-
ases were induced with 1 mM of IPTG when growing in early
xponential phase (OD600 = 0.7), and temperature was  dropped to
0 ◦C until harvesting. Cells were harvested by centrifugation after
 h of induction, and stored at −20 ◦C. 15 min  before harvesting
yridoxal-5′-phosphate (PLP) was added to the cells expressing5-CTCGAGGGCGGCCGGTTCTTTCGCGGTCAG-3
5-CTCGAGGCCTTGGTACAGGCCAAGCGCCGT-3
5-CTCGAGGGCGGCCGGTTCTTTCGCGGTCAG-3
the transaminases at a ﬁnal concentration of 400 M to improve
enzyme activity.
The cell pellet after induction was  resuspended in 50 mM
Tris–HCl pH: 8.0 and 400 M PLP at a 1:25 volume ratio (1 ml  of
the resuspension buffer per 25 ml  of cell suspension); and sonicated
(Soniprep 150 sonicator, MSE  Sanyo Japan) on ice using 10 cycles of
10 s On, 10 s Off at 10 . The sonicated suspension was centrifuged
at 13.000 rpm at 4 ◦C for 60 min. Puriﬁcation was carried out by
nickel afﬁnity using His-Select®Nickel Afﬁnity Gel (Sigma–Aldrich,
USA), following manufacturer recommendations, and supplement-
ing each of the buffers with 400 M PLP. 250 mM of imidazole was
added to the eluted enzyme and was removed using PD-10 columns
(General Electric, USA) with 50 mM Tris–HCl pH: 8.0 and 400 M
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Fig. 3. Conversion of HPA  obtained from bioconversions using 12 different transam-6 M.F. Villegas-Torres et al. / Enzyme a
LP as desalting buffer. Bradford reagent (Sigma–Aldrich, USA) was
se for total protein concentration quantiﬁcation [19] with bovine
erum albumin (BSA) (Sigma–Aldrich, USA) as standard. Enzyme
urity was conﬁrmed by SDS-PAGE using 12% Tris-Glycine Precast
els (Invitrogen, USA).
.4. Enzyme reactions
Commercially available substrates were purchased from
igma–Aldrich (unless otherwise stated). ABT was  chemically
ynthesised following the method by Dequeker et al. [20] and
15]. The 1,2-acetonide benzylamine diastereomeric intermediates
ere separated by silica ﬂash column chromatography (parti-
le size 40–63 m)  to give the (2R,3S)-ABT after subsequent
eprotections. Racemic ketodiols 1,3-dihydroxypentan-2-one,
,3-dihydroxyhexan-2-one, 1,3-dihydroxyheptan-2-one and 1,3-
ihydroxyoctan-2-one were synthesised as described previously
sing an N-methylmorpholine-catalysed biomimetic reaction in
ater [21–23]. 6-Aminoquinolyl-N-hydroxysuccinimidyl carba-
ate (AQC) was synthesised according to Cohen and Michaud [24].
ll reactions were performed in 2 ml  glass vials at 30 ◦C and 350 rpm
n 50 mM Tris–HCl pH 8.0, containing: 400 M PLP; substrates
hich varied according to the experiment performed; 0.3 mg/ml  of
ransaminase; and 0.1 mg/ml  of transketolase enzyme or otherwise
tated, 9 mM  MgCl2 and 2.4 mM TPP when studying the coupled
ystems. Prior to the addition of the enzyme(s), substrates were
re-incubated for 15 min  at 30 ◦C and 350 rpm in a Thermomixer
omfort shaker (Cambridge, UK). Transketolase enzyme was also
re-incubated with 9 mM MgCl2 and 2.4 mM TPP at 25 ◦C for 20 min,
hen required. After the reaction, 80 l aliquots were quenched
ith 80 l of 0.2% TFA. All samples were analysed by HPLC.
.5. HPLC detection method and enantiopurity determination
HPA, pyruvate and erythrulose detection, no higher than 10 mM,
as carried out by injecting 20 l samples into a Dionex X500HPLC
Camberley, UK) comprising a Famos 120 autosampler, an Ultimate
000 generation II isocratic pump, a LC30Chromatography column
ven, and an AD20 Absorbance Detector. The system was  equipped
ith an Aminex HPX-87H Ion exchange column (300 mm×7.8 mm;
io-Rad, Hemel Hempstead, UK) run at 60 ◦C with 0.6 ml/min iso-
ratic ﬂow of 0.1% TFA as mobile phase. Detection was  performed by
V absorbance at 210 nm and peak identiﬁcation and quantiﬁcation
ere carried out using Chromeleon client 6.80 software. Commer-
ially available standard compounds were analysed in parallel with
he samples. The retention time of detected compounds are as
ollows: HPA: 8.3 min; pyruvate: 9.9 min; erythrulose: 11.5 min.
erine and ABT detection was performed by derivatising 75 l
amples with 150 l of 10 mg/ml  AQC in dry acetonitrile; fol-
owed by the addition of 225 l of 0.2 M borate buffer pH: 5.
50 l derivatised samples were injected into a Dionex Ultimate
000HPLC (Camberley, UK) with a ACE 5C18 reverse phase column
150 mm ×4.6 mm,  5 m particle size; Advance Chromatography
echnologies, Aberdeen, UK) controlled by Chromeleon client 6.80
oftware, implementing the method developed by Ingram et al.
For analysis of the enantiopurity of ABT formed in the biocat-
lytic reaction, it was isolated and analysed by NMR  spectroscopy
Bruker Avance-600 MHz  spectrometer recorded at 296 K). Com-
arison of NMR  spectra of the ABT generated in this work to ABT
ynthesised chemically (using an identical method to that previ-
usly reported by Ingram and colleagues [15]) indicated that only
ne isomer was formed (within detection levels) in the enzymatic
ascade.inases. Reactions were carried out with 10 mM pyruvic acid and l-serine. HPA
concentration was quantiﬁed after a 2 h reaction by HPLC (see Section 2 for details).
Data are the means of three independent reactions ± SE.
3. Results
3.1. Serine:pyruvate transaminase identiﬁcation and selection
All the proposed cascades in this work depend on a transam-
inase able to either aminate pyruvate or erythrulose using serine
as an amine donor (Figs. 1 and 2). It has been reported that -
transaminases are active with serine at a very low rate [9,16];
but there is not a clear description of an -transaminase that
employs serine as amine donor. As a result, from previous studies
in our group 12 transaminases from different organisms (Table 1)
were identiﬁed as possible catalytic candidates for the synthesis
of HPA from serine by colorimetric screening assays. To corrob-
orate the initial results and identify the enzymes with highest
conversions under our reaction conditions, a quantitative assay was
employed to determine the amount of HPA generated when using
10 mM of both pyruvate and L-serine as substrates (Fig. 3). After
2 h of reaction, DGEO 0713 (Deinococcus geothermalis), RSPH17025-
2835 (Rhodobacter sphaeroides) and RSPH17029-3177 (Rhodobacter
sphaeroides) synthesised 2.5 mM,  1.6 mM  and 2.8 mM of HPA,
respectively. As a comparison the conversion achieved by the
CV2025 transaminase was 1.1 mM of HPA, which had been pre-
viously reported as able to use serine as an amine donor [16]. The
above enzymes were therefore selected for further kinetic analysis
and amine acceptors proﬁle studies.
3.2. Enzyme characterisation: kinetic parameters and amine
acceptors proﬁle
In Table 3 the kinetic parameters are shown when using L-
serine as an amine donor and pyruvate as the amine acceptor
for CV2025, DGEO 0713, RSPH17025 2835 and RSPH17029 3177
transaminases. DGEO 0713 was the most efﬁcient enzyme using
serine as amine donor, as it had the highest afﬁnity towards the
compound in spite of its low turnover number, and was the only
enzyme not inhibited by pyruvate. Conversely, RSPH17029 3177
showed the lowest afﬁnity towards serine, while the catalytic con-
stant was  the highest among the four enzymes tested.
From the amino acid sequences CV2025, RSPH17025 2835 and
RSPH17029 3177 were classiﬁed as -transaminases indicating a
potential broad substrate tolerance with the ability to act on alde-
hydes, ketones and keto acids [10,16,25]. Alternatively, DGEO 0713
was classiﬁed as an -transaminase, and thus it would be expected
to be more restricted with respect to the range of substrates
accepted [26,10].
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Table  3
Kinetic parameters of the transaminases CV2025, DGEO 0713, RSPH17025 2835, RSPH17029 3177.
Transaminase Substrate KM (mM)  kcat (min−1) kcat/KM(mM−1 × min−1)
CV2025 Serinea 148 64 0.4
Erythruloseb 37.7 2.9 0.08
DGEO 0713 Serine 18 28 1.55
Pyruvatec 9.6 56 5.9
RSPH17025 2835 Serine 300.4 91 0.3
Erythrulose 75.4 11 0.15
RSPH17029 3177 Serine 367 147.5 0.4
Erythrulose 65.4 17.6 0.27
a 10 mM of pyruvic acid and varying l-serine concentrations from 5 mM to 200 mM were used.
b 80 mM of l-serine and varying erythrulose concentrations between 5 mM and 200 mM were used.
c 80 mM of l-serine and varying pyruvic acid concentrations between 5 mM and 200 mM were used.
Table 4
Amine acceptors proﬁle of the transaminases CV2025, DGEO 0713, RSPH17025 2835, RSPH17029 3177.
Amine acceptor CV2025 DGEO 0713 RSPH17025 2835RSPH17029 3177
Conv.a (mM)Initial ratea (mM/min)Conv. (mM)  Initial rate (mM/min)Conv. (mM)Initial rate (mM/min)Conv. (mM)Initial rate (mM/min)
Aldehydes
Glycolaldehyde 5.9 0.02 n.r.b n.r. 7.8 0.04 7.2 0.04
Propanaldehyde 4.2 0.03 n.r. n.r. 5.6 0.07 5.7 0.07
Butyraldehyde 6.3 0.04 n.r. n.r. 6.7 0.1 6.8 0.1
Valeraldehyde 7.2 0.02 n.r. n.r. 8.3 0.05 8.4 0.05
Hexanaldehyde 5.4 0.01 n.r. n.r. 7.0 0.09 7.0 0.1
Ketones
Erythrulose 0.7 0.001 n.r. n.r. 1.9 0.005 2.4 0.01
1,3-Dihydroxypentan-2-one2.0 0.008 0.8 0.002 1.4 0.008 1.6 0.008
1,3-Dihydroxyhexan-2-one 1.6 0.007 n.r. n.d 2.2 0.01 2.1 0.01
1,3-Dihydroxyheptan-2-one1.0 0.006 n.r. n.d 1.4 0.007 1.5 0.008
1,3-Dihydroxyoctan-2-one 0.6 0.001 n.r. n.r. 1.1 0.0009 1.1 0.008
Keto  acids
Pyruvic acid 7.4 0.03 7.5 0.13 10.4 0.1 10.8 0.1
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sa 80 mM of l-serine and 10 mM of the corresponding amine acceptor were used
PA  production from serine in a HPLC.
b Not reactive: HPA levels below the detection limit 0.005 mM.
To conﬁrm the above classiﬁcations and test whether the
nzymes were able to synthesise ABT and additional analogues for
uture applications, other aliphatic aldehydes were selected that
re accepted by transketolase wild type or described mutants, and
he ketodiols produced from the corresponding reactions [23].
The data obtained (Table 4) conﬁrmed the above classiﬁca-
ion when using serine as an amine donor: all -transaminases
eacted with the aliphatic aldehydes, ketones and keto acids tested
ith conversions in the 1–9 mM range; whereas DGEO 0713 was
nly active with pyruvate. Regarding the use of aldehydes as
mine acceptors both RSPH17025 2835 and RSPH17029 3177 were
pproximately 2-times faster CV2025, and a higher conversion of
irca 10% was  noted compared to CV2025. All -transaminases
mproved their activity when the length of aliphatic side chain
ncreased except CV2025, which decreased for chain lengths longer
han butanal with an increasing number of carbon residues. With
ihydroxyketones as amine acceptors, both RSPH17025 2835 and
SPH17029 3177 were approximately 3-times faster than CV2025.
owever, while RSPH17025 2835 decreased its activity gradually
pon increasing the length of the alkyl chain, RSPH17029 3177 had
 constant activity as the chain length increased. The transami-
ases had negligible activity towards 1,3-dihydroxyoctan-2-one,
he ketone tested possessing the longest alkyl chain.
As shown in Fig. 1, the sequential pathway requires a transam-
nase able to speciﬁcally use serine and pyruvate as substrates
or the ﬁrst step, as well as the CV2025 transaminase previously
escribed for the ﬁnal step of the cascade [16,17]. Based on the
haracteristics described above, the best choice was  DGEO 0713
ecause it was not inhibited by pyruvate and was  not active
ith any of the other compounds present. Alternatively, the two-
tep recycling cascade (Fig. 2) depends on a transaminase ablestrates and both conversions (Conv.) and initial reaction rates were measured by
to aminate ketones using serine as amine donor. From the data
shown in Table 4, the best candidates were RSPH17025 2835
and RSPH17029 3177, as both were active towards a broad
range of amine acceptors, synthesising ABT, 2-aminopentane-
1,3-diol, 2-aminohexane-1,3-diol, 2-aminoheptane-1,3-diol and
2-aminooctane-1,3-diol. Also, they were 2-times faster than
CV2025, previously used for ABT synthesis [17]. Based on the
kinetic data (Table 3) for erythrulose, the most efﬁcient enzyme was
RSPH17029 3177, showing the highest catalytic constant and afﬁn-
ity for this particular ketone; therefore this enzyme was employed
for the transamination step.
3.3 ABT synthesis using two different de novo pathways
To test whether each of the cascades could be implemented in
the synthesis of chiral amino alcohols ABT was used as a case study,
because it could be compared with previous reports [15,17], and the
activity of the transketolase enzyme has been widely characterised
for the synthesis of erythrulose where it shows a strong activity
towards the substrates involved [27–31].
The sequential strategy shown in Fig. 1 involved a transami-
nation step, performed by the enzyme DGEO 0713 using serine
and pyruvate as substrates, followed by the previously described
de novo pathway implementing CV2025 transaminase [15,17]. This
enzyme is an -transaminase active with ketones, aldehydes and
keto acids [26,10,16], such as erythrulose, GA and pyruvate; there-
fore, the effectiveness of the system was tested in two sequential
steps to avoid side reactions. The ﬁrst step is a one-pot pathway
of two enzymatic steps where DGEO 0713 transaminase catalysed
the production of HPA, the substrate for the subsequent transketo-
lase step required for the synthesis of erythrulose; and the second
28 M.F. Villegas-Torres et al. / Enzyme and Microbial Technology 81 (2015) 23–30
Fig. 4. Reaction proﬁle for the synthesis of ABT via the three-step sequential path-
way  using 0.5 mg/ml  pure DGEO 0713, 0.3 mg/ml pure transketolase, and 1 mg/ml
pure CV2025. Reactions were carried out with 100 mM l-serine, 50 mM pyruvate,
50  mM GA and 10 mM MBA. Erythrulose, pyruvate, HPA and ABT were quantiﬁed
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Fig. 5. Reaction proﬁles for the synthesis of ABT through the two-step recycling
cascade using 1 mg/ml  pure RSPH17029 3177 and 0.1 mg/ml pure transketolase,ver time for 55 h by HPLC (see Section 2 for details). The dotted line represents the
ime of CV2025 and MBA  addition causing 1:2 dilution of the synthesised erythulose.
ata are the means of three independent reactions ± SE.
tep is the transamination of erythrulose by CV2025 [16,17]. We
mplemented a higher serine concentration in order to shift the
quilibrium of the ﬁrst step towards the product HPA and to ensure
hat the pyruvate and the GA were fully consumed. Fig. 4 shows the
eaction proﬁle of the system over approximately 55 h. The ﬁrst 24 h
orrespond to the synthesis of erythrulose giving a ﬁnal conversion
f 43.7 mM of erythrulose and 3.5 mM of HPA as intermediate prod-
cts, leaving 3 mM of unreacted pyruvate. The following 31 h of
eaction corresponds to the ﬁnal transamination step that resulted
n 3% conversion of ABT based on the concentration of MBA  added,
nd the consumption of the remaining pyruvate and HPA, which
re preferable substrates for the CV2025 transaminase [16]. A con-
entration of 10 mM of MBA  was used to avoid inhibition by this
ubstrate [8,17]. Isopropylamine (IPA) was also tested as an alter-
ative amine donor, as a higher conversion of ABT was  previously
eported when using IPA rather than MBA  in a two-step coupled
eaction [17]. In contrast to this result, when implemented in a
hree-step coupled reaction, ABT was not detected after 50 h reac-
ion (see Supplementary information, Fig. 2) (Fig. 5).
The two-step recycling cascade shown in Fig. 2 is a co-product
ecycling mechanism, in which a transaminase catalyses the ami-
ation of erythrulose using serine as amine donor for the synthesis
f ABT and HPA. HPA is then used as 2-carbon donor by a
ransketolase-catalysed reaction with GA as keto acceptor for the
rreversible synthesis of erythrulose and the release of carbon diox-
de. Because of the recycling nature of the system the reaction
equired an initial input of HPA, either manually or from an alter-
ative reaction, such as the amination of GA with serine, resulting
n the production of the required HPA and ethanolamine as a side
roduct (Fig. 2).
Based on the kinetic constants previously determined it was
lear that in order to synthesise ABT using the two-step recycling
ystem (Fig. 2), a high serine concentration will be required to
rive the reaction forward, and it has been reported that concen-
rations above 40 mM of GA inhibits the TK reaction [30]. Based
n our previous work [17] a 3:1 ratio of transaminase to transke-
olase was implemented, achieving 50% conversion of erythrulose
20 mM)  from GA, as half of the GA is probably consumed in the side
eaction with serine. Thus based on the concentration of erythru-
ose synthesised, 18% ABT conversion was obtained or 9% overall100 mM l-serine and 40 mM GA. Erythrulose, HPA and ABT were quantiﬁed over
time for 50 h by HPLC (see Section 2 for details). Data are the means of three inde-
pendent reactions ± SE.
ABT conversion based on the GA initial concentration. It was not
expected to achieve a 100% conversion of erythrulose due to the
higher afﬁnity (KM: 7.9 mM)  and higher turnover (kcat: 21.2 min−1)
of the transaminase towards GA compared to erythrulose (Table 3)
when using serine as amine donor. Finally, after 55 h reaction
there was an evident depletion of HPA over time, which could be
attributed to the chemical degradation as reported by Rios-Solis
et al.
One of the main beneﬁts of using enzymes as catalysts for chem-
ical synthesis is their enantioselectivity and enantiospeciﬁcity that
simpliﬁes the downstream processing. An ee > 95% was  determined
for the ABT synthesised using RSPH17029 3177 with L-serine and
erythrulose as substrates. A 95% ee was also reported by Rios-Solis
and colleagues [17] when synthesising ABT from MBA  and erythru-
lose using CV2025.
4. Discussion
The sequential pathway (Fig. 1) is an interesting approach for
chiral amino alcohol synthesis as it is not restricted by an -
transaminase able to aminate ketones using serine as amine donor.
Therefore, this pathway could be used to produce a more diverse set
of chiral amino alcohols than the two-step recycling cascade. How-
ever, when tested for ABT synthesis it was  clearly compromised by
the presence of residual substrates (pyruvate, GA and HPA) from
the previous enzymatic steps, as they are preferable substrates for
the CV2025 enzyme, despite the surplus of serine, pushing the reac-
tion towards the product side [16]. In addition, the increase in ABT
concentration did not correlate with the consumption of erythru-
lose, which can be attributed to ABT or erythrulose degradation
either caused by the components in the reaction or by the enzymes.
Finally, the implementation of an alternative amine donor that has
shown better conversions in other studies [17] had a detrimental
effect on this system. A result, in spite of its potential to produce
a wide range of chiral compounds, it has difﬁcult biological and
engineering challenges that need to be addressed.
On the other hand, the two-step recycling cascade system (Fig. 2)
described in this work is a novel approach for the synthesis of
chiral amino alcohols. The recycling of the co-product is an attrac-
tive de novo pathway to integrate with the host metabolism as
only two  natural substrates are required: serine which is natu-
rally synthesised and has been overproduced [32–34]; and GA is
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ound in the biosynthetic pathway of folic acid, in the pentose
nd glucuronate interconversions, and vitamin B6, glyoxylate and
icarboxylate metabolism [18]. This pathway only consists of two
nzymatic steps, thereby decreasing the metabolic burden gener-
ted by their overexpression and simplifying the expression system
equired to achieve the necessary enzyme levels within the host.
he side reaction catalysed by the transaminase is required for
he cascade to take place, having a relatively positive effect on the
BT synthesis, and avoiding the sequential addition of enzymes to
ncrease ﬁnal yields as described elsewhere [14]. In conclusion, it is
ot only more efﬁcient than the sequential pathway (6-fold higher
onversion), but it is more sustainable and cost-effective.
The two-step recycling cascade requires an enzyme able to
minate both aldehydes and ketones with serine as the amine
onor, which has not been reported in the literature to date, as
he available transaminases have no or very low activity with the
bove substrates [35,9,16]. Consequently, several new transami-
ases were identiﬁed and characterised: two new -transaminases
RSPH17025 2835 and RSPH17029 3177) with better activity than
he transaminase from C. violaceum [16], when using serine
s amine donor; and a highly selective serine transaminase
DGEO 0713) with high activity towards its substrates serine and
yruvate. The two -transaminases are very similar in both DNA
equence and substrate proﬁle, but RSPH17029 3177 possess a
igher afﬁnity towards serine and has larger turnover number than
SPH17025 2835.
The implementation of the enzyme RSPH17029 3177 in the cas-
ade proved the system’s feasibility for the synthesis of ABT by
upplying GA and serine, and its potential for metabolic integration.
n addition, according to the substrates proﬁle RSPH17029 3177
s capable of aminating various aliphatic ketones, and so differ-
nt aliphatic chiral amino alcohols could be potentially produced
sing the two-step recycling cascade, such as 2-aminopentane-
,3-diol, 2-aminohexane-1,3-diol, 2-aminoheptane-1,3-diol and
-aminooctane-1,3-diol.
It is important to take into account that the two-step recycling
ascade has two main limitations that restrict the possible maxi-
um  conversion. One is the differential activity of the transaminase
owards GA and erythrulose, whereby GA is preferred by the
nzyme; resulting in a large consumption of the GA by the side
eaction. The other constraint is the equilibrium of the transamina-
ion reaction, which cannot be shifted by the transketolase reaction.
his is because the HPA produced by the amination of erythrulose
annot be fully consumed because GA has been fully depleted by
he transaminase side reaction with serine and GA as substrates.
o fully overcome the system’s limitations the transaminase could
e engineered to improve its afﬁnity to ketones, and reduce it to
ldehydes.
In a previous study, an acetohydroxyacid synthase was cou-
led to CV2025 for the synthesis of (1R,2S)-norephedrine (NE)
rom benzaldehyde, pyruvate and alanine as substrates [14], fol-
owing a similar reaction scheme to the two-step recycling cascade
escribed in this work. The above cascade recycles the pyruvate
ubstrate using two enzymes but requiring three substrates rather
han two. When the cascade was performed in one-pot a 2% conver-
ion was achieved based on the pyruvate concentration (10 mM).
he ﬁnal conversion was further 40-times improved by adding the
nzymes sequentially to the reaction. In spite of the higher conver-
ion, when implemented in a whole cell system the synthesis of
E presents more limitations than the two-step recycling system
escribed here. It requires the addition of three different substrates
nd, the enzymes must be ﬁnely expressed in a sequential manner
o achieve high conversions. As a result its metabolic integration is
ore complex than the system described in this work.
In summary, this work describes a -transaminase able to
minate pyruvate using serine as amine donor with high sub-
[
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strate speciﬁcity; and two novel -transaminases that are more
active than the previously described -transaminase from C. vio-
laceum CV2025 under our reaction conditions and substrates are
described; therefore they should be explored further for their
implementation in alternative bioconversion processes. We  have
characterised a novel cascade for the synthesis of chiral amino
alcohols that involves a two-step recycle system of the co-product.
The implementation of recycling steps within several cascades has
been described [36–40], but to the best of our knowledge none of
them involve the use of serine as amine donor; as a result our work
demonstrates the feasibility of this approach.
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